Bexicaserin is under clinical development by Longboard Pharmaceuticals and currently in Phase II for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). According to GlobalData, Phase II drugs for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bexicaserin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bexicaserin overview
Longboard Pharmaceuticals overview
Longboard Pharmaceuticals (Longboard) is a clinical-stage biopharmaceutical company that discover and develops novel, transformative medicines for neurological diseases. The company’s pipeline program includes LP352, an oral 5-HT2c super agonist targeting dravet syndrome, lennox-gastaut syndrome (LGS), CDKL5 deficiency disorder, tuberous sclerosis complex (TSC), and other epileptic disorders; LP143, a CB2 agonist against amyotrophic lateral sclerosis (ALS) and neuroinflammatory disorders; and LP659, S1P receptor modulator targeting multiple neuroinflammatory disorders. It is also developing medicines for the treatment of central nervous system neuroinflammatory diseases and epileptic encephalopathies. Longboard is headquartered in La Jolla, California, the US
For a complete picture of Bexicaserin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
